Abstract
In 352 patients with primary open-angle glaucoma or ocular hypertension, a multicenter double-masked, parallel-group clinical study compared the effects on intraocular pressure and ocular comfort of 0.5% betaxolol ophthalmic solution, a cardioselective beta-adrenergic blocking agent, with 0.25% betaxolol suspension. With twice-daily dosages, baseline intraocular pressure was significantly reduced (P = .0005), with no significant difference between the two groups, at Week 2 and at Months 1, 2, and 3. Further, the prevalence of ocular discomfort upon topical instillation was significantly lower for 0.25% betaxolol suspension than for 0.5% betaxolol solution (P = .0005).
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Topical
-
Analysis of Variance
-
Betaxolol / administration & dosage*
-
Betaxolol / adverse effects
-
Betaxolol / therapeutic use
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Female
-
Glaucoma, Open-Angle / drug therapy*
-
Humans
-
Intraocular Pressure / drug effects
-
Male
-
Middle Aged
-
Multicenter Studies as Topic
-
Ocular Hypertension / drug therapy*
-
Ophthalmic Solutions / administration & dosage
-
Ophthalmic Solutions / therapeutic use
-
Randomized Controlled Trials as Topic
-
Suspensions / administration & dosage
-
Suspensions / therapeutic use
Substances
-
Ophthalmic Solutions
-
Suspensions
-
Betaxolol